InVivo gets FDA OK for spinal trial; IMS gears up for $100M IPO;

@FierceMedDev: The CFO of troubled Mela Sciences resigned on Dec. 31. CEO Rose Crane is filling in. Release | Follow @FierceMedDev

@MichaelGFierce: Gene therapy technique from Washington University in St. Louis targets tumor blood vessels. Article | Follow @MichaelGFierce

@GalenMoore: Drug companies accused of holding back complete information on clinical trials. Story | Follow @GalenMoore

> InVivo Therapeutics ($NVIV) secured FDA approval to kick off its first clinical trial for an in-development spinal scaffold. Article

> IMS Health, which provides prescription and procedure data to drug and medical device companies, has filed for a $100 million IPO. News

> In its nearly 20 years in business, Luminex ($LMNX) has risen from small-staffed specialist to a heavyweight in diagnostics. Story

Biotech News

@FierceBiotech: Marina Biotech, Mirna Therapeutics amend license deal to develop microRNA-based therapeutics. Release | Follow @FierceBiotech

@JohnCFierce: Top FierceBiotech story yesterday: Is it human, animal or plant? At Bayer, they're mixing all three in new R&D recipe. More | Follow @JohnCFierce

@DamianFierce: The long, strange trip that was Wright Medical's 2013. Report | Follow @DamianFierce

@EmilyMFierce: Cancer Research UK to repurpose an AstraZeneca asthma drug for kidney cancer. Story from FierceBiotech Research | Follow @EmilyMFierce

> Ambitious HDL program joins a growing list of high-profile clinical failures. Story

> A step ahead of controversial transparency rules, Sanofi commits to open access. Report

> NeXeption raises $21.5M to launch dermatology startup Alexar. Article

Pharma News

@FiercePharma: Rakesh Bamzai Joins Mylan as President, India Commercial and Emerging Markets. Release | Follow @FiercePharma

@EricPFierce: Merck is cutting 150 in its Saphris sales team after selling the drug to Forest for $240M. More | Follow @EricPFierce

@CarlyHFierce: Cue more drama in Teva's boardroom as its CEO announcement nears. Yesterday's story | Follow @CarlyHFierce

> Bayer's hot-selling Eylea runs into a roadblock in its home market. Story

> Mylan has hired away a new India president from Biocon, its partner there. Report

> China clears hep B vaccine makers in child deaths. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Everlywell’s sales of at-home diagnostic tests, including one kit for COVID-19, are projected to quadruple this year—and investors have taken notice.

The Tel Aviv-based VC firm focused on digital health has closed a new fund totaling $170 million, with plans to expand to the Asia Pacific region.

LivaNova will sell off its flagging heart valve business to the Swiss firm Gyrus Capital, for a base purchase price of €60 million.